NBE-Therapeutics engages in the development of “next-generation”, immune-stimulatory antibody drug conjugates (iADCs) with the objective to develop best-in-class ADC product candidates until clinical proof-of-concept in patients.
NBE Therapeutics joined the Boehringer-Ingelheim group of companies.
Products, services, technology
NBE-002, an anti-ROR1 iADC
Technology and early ADC development candidate partnering for joint development into the clinic.